secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001628280-26-017259
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q3: study service rev record $16.6M (+32%); net loss $279k vs prior yr profit $4.5M
--------------------------------------------------------------------------------

- Record study service revenue $16.6M, up 32% YoY; total revenue $16.6M vs $17.0M prior year.
- GAAP net loss of $279k (incl $423k stock comp, $341k D&A) vs net income $4.5M prior year.
- Adjusted EBITDA $574k, down from $5.1M prior year; cost margins compressed by outsourced radiolabeling.
- Ended quarter with $7.1M cash, no debt; management reaffirms full-year positive adj. EBITDA and revenue growth.
- R&D expense $2.3M, up 32% for data platform and Corellia investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/0001628280-26-017259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/csbr-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-017259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer